Sernova Biotherapeutics【SVA】銘柄情報

Sernova Biotherapeutics Inc (SVA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.145

( -6.45% )

買値

0.145

売値

0.15

出来高

129,330

0.14 日の範囲 0.155

0.12 52 週間の範囲 0.21

時価総額

54.665M

前日終値

0.155

始値

0.155

時刻

1500

0.145

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

$ 118,569

発行済株式数

377,000,009

配当利回り

PER

-4

1 株当たり利益 (EPS)

-0.04

歳入

純利益

-12.38M

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longe... Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.sernova.com

本社

Mississauga, Canada

設立

Sernova Biotherapeutics Inc is listed in the Healthcare sector of the トロント証券取引所 with ticker SVA. The last closing price for Sernova Biotherapeutics was $0.16. Over the last year, Sernova Biotherapeutics shares have traded in a share price range of $ 0.12 to $ 0.21.

Sernova Biotherapeutics currently has 377,000,009 shares in issue. The market capitalisation of Sernova Biotherapeutics is $54.67 million. Sernova Biotherapeutics has a price to earnings ratio (PE ratio) of -4.00.

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

VANCOUVER, British Columbia, Dec. 16, 2025 (GLOBE NEWSWIRE) -- USA News Group News Commentary – Stanford...

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB:...

Sernova Appoints Jonathan Rigby as Interim Chair

LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

Chair of Sernova Biotherapeutics Resigns

LONDON, Ontario and BOSTON, May 26, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

LONDON, Ontario and BOSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Clinical Study on Track to Meet its Primary and Secondary Endpoints Data Demonstrate That Metabolic Measures...

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

LONDON, Ontario and BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

LONDON, Ontario and BOSTON, April 15, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

DSMB supports advancement for Sernova’s clinical trial Study is on track to meet key clinical trial endpoints...

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB:...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.005	-3.33333333333	0.15	0.16	0.14	82924	0.15250379	CS
4	-0.01	-6.45161290323	0.155	0.17	0.135	117038	0.14795524	CS
12	-0.015	-9.375	0.16	0.2	0.135	119991	0.16279032	CS
26	0.005	3.57142857143	0.14	0.2	0.12	116404	0.15713783	CS
52	-0.02	-12.1212121212	0.165	0.21	0.12	108758	0.16131771	CS
156	-0.735	-83.5227272727	0.88	1.1	0.12	128096	0.33761523	CS
260	-1.405	-90.6451612903	1.55	1.59	0.12	126895	0.50406339	CS

SVA - Frequently Asked Questions (FAQ)

What is the current Sernova Biotherapeutics Inc share price?

The current share price of Sernova Biotherapeutics Inc is $ 0.145

How many Sernova Biotherapeutics Inc shares are in issue?

Sernova Biotherapeutics Inc has 377,000,009 shares in issue

What is the market cap of Sernova Biotherapeutics Inc?

The market capitalisation of Sernova Biotherapeutics Inc is CAD 54.67M

What is the 1 year trading range for Sernova Biotherapeutics Inc share price?

Sernova Biotherapeutics Inc has traded in the range of $ 0.12 to $ 0.21 during the past year

What is the PE ratio of Sernova Biotherapeutics Inc?

The price to earnings ratio of Sernova Biotherapeutics Inc is -4

What is the registered address of Sernova Biotherapeutics Inc?

The registered address for Sernova Biotherapeutics Inc is RPO Central Parkway, Mississauga, Ontario, L5A 4H2

What is the Sernova Biotherapeutics Inc website address?

The website address for Sernova Biotherapeutics Inc is www.sernova.com

Which industry sector does Sernova Biotherapeutics Inc operate in?

Sernova Biotherapeutics Inc operates in the Biotechnology & Life Sciences sector

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sernova Biotherapeutics Inc (SVA)

Sernova Biotherapeutics Inc (SVA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Sernova Biotherapeutics Inc について

SVA 最新ニュース

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Sernova Appoints Jonathan Rigby as Interim Chair

Chair of Sernova Biotherapeutics Resigns

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

SVA - Frequently Asked Questions (FAQ)

SVA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Sernova Biotherapeutics Inc (SVA)

Sernova Biotherapeutics Inc (SVA) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

主要統計と詳細

Sernova Biotherapeutics Inc について

SVA 最新ニュース

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

Sernova Appoints Jonathan Rigby as Interim Chair

Chair of Sernova Biotherapeutics Resigns

Sernova Biotherapeutics Appoints World-Class Clinical Advisory Board to Support Development of Cell Pouch Bio-hybrid Organ as Functional Cure for Type 1 Diabetes

Sernova Biotherapeutics Provides Positive Interim Data from Ongoing Phase 1/2 Clinical Trial of Cell Pouch Bio-hybrid Organ in Patients Living with Type 1 Diabetes

Sernova Biotherapeutics Secures $4 Million Loan to Further Advance its Clinical Development Plans

Sernova Biotherapeutics Cell Pouch Bio-hybrid Organ to be Highlighted at Cell & Gene Meeting on the Med

Sernova Biotherapeutics Provides Update on Phase 1/2 Clinical Trial of Cell Pouch™ Bio-Hybrid Organ for Treatment of Type 1 Diabetes

Sernova Biotherapeutics Appoints Pericles Calias, Ph.D. as Chief Development Officer and Head of R&D

From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes

Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

SVA - Frequently Asked Questions (FAQ)

SVA 取引

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する